https://www.selleckchem.com/pr....oducts/combretastati
More research is needed into the risk factors for pre-menopausal breast cancer to support primary prevention efforts in this area.Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, t
Like
Comment
Share
